410 related articles for article (PubMed ID: 30284145)
1. In vivo epigenome editing and transcriptional modulation using CRISPR technology.
Lau CH; Suh Y
Transgenic Res; 2018 Dec; 27(6):489-509. PubMed ID: 30284145
[TBL] [Abstract][Full Text] [Related]
2. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells.
Okada M; Kanamori M; Someya K; Nakatsukasa H; Yoshimura A
Epigenetics Chromatin; 2017; 10():24. PubMed ID: 28503202
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
Tadić V; Josipović G; Zoldoš V; Vojta A
Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
[TBL] [Abstract][Full Text] [Related]
4. Epigenome editing of the CFTR-locus for treatment of cystic fibrosis.
Kabadi AM; Machlin L; Dalal N; Lee RE; McDowell I; Shah NN; Drowley L; Randell SH; Reddy TE
J Cyst Fibros; 2022 Jan; 21(1):164-171. PubMed ID: 34049825
[TBL] [Abstract][Full Text] [Related]
5. Establishment of Cell Lines Stably Expressing dCas9-Fusions to Address Kinetics of Epigenetic Editing.
Goubert D; Koncz M; Kiss A; Rots MG
Methods Mol Biol; 2018; 1767():395-415. PubMed ID: 29524148
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/dCas9 platforms in plants: strategies and applications beyond genome editing.
Moradpour M; Abdulah SNA
Plant Biotechnol J; 2020 Jan; 18(1):32-44. PubMed ID: 31392820
[TBL] [Abstract][Full Text] [Related]
7. Transgenic mice for in vivo epigenome editing with CRISPR-based systems.
Gemberling MP; Siklenka K; Rodriguez E; Tonn-Eisinger KR; Barrera A; Liu F; Kantor A; Li L; Cigliola V; Hazlett MF; Williams CA; Bartelt LC; Madigan VJ; Bodle JC; Daniels H; Rouse DC; Hilton IB; Asokan A; Ciofani M; Poss KD; Reddy TE; West AE; Gersbach CA
Nat Methods; 2021 Aug; 18(8):965-974. PubMed ID: 34341582
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/dCas9 Switch Systems for Temporal Transcriptional Control.
Gjaltema RAF; Schulz EG
Methods Mol Biol; 2018; 1767():167-185. PubMed ID: 29524134
[TBL] [Abstract][Full Text] [Related]
9. Targeting cancer epigenetics with CRISPR-dCAS9: Principles and prospects.
Rahman MM; Tollefsbol TO
Methods; 2021 Mar; 187():77-91. PubMed ID: 32315755
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas mediated epigenome editing for cancer therapy.
Ansari I; Chaturvedi A; Chitkara D; Singh S
Semin Cancer Biol; 2022 Aug; 83():570-583. PubMed ID: 33421620
[TBL] [Abstract][Full Text] [Related]
11. A modular dCas9-SunTag DNMT3A epigenome editing system overcomes pervasive off-target activity of direct fusion dCas9-DNMT3A constructs.
Pflueger C; Tan D; Swain T; Nguyen T; Pflueger J; Nefzger C; Polo JM; Ford E; Lister R
Genome Res; 2018 Aug; 28(8):1193-1206. PubMed ID: 29907613
[TBL] [Abstract][Full Text] [Related]
12. Editing the Epigenome to Tackle Brain Disorders.
Liu XS; Jaenisch R
Trends Neurosci; 2019 Dec; 42(12):861-870. PubMed ID: 31706628
[TBL] [Abstract][Full Text] [Related]
13. Advances of epigenetic editing.
Gjaltema RAF; Rots MG
Curr Opin Chem Biol; 2020 Aug; 57():75-81. PubMed ID: 32619853
[TBL] [Abstract][Full Text] [Related]
14. Allele-Specific Epigenome Editing.
Bashtrykov P; Jeltsch A
Methods Mol Biol; 2018; 1767():137-146. PubMed ID: 29524132
[TBL] [Abstract][Full Text] [Related]
15. A modular dCas9-based recruitment platform for combinatorial epigenome editing.
Swain T; Pflueger C; Freytag S; Poppe D; Pflueger J; Nguyen TV; Li JK; Lister R
Nucleic Acids Res; 2024 Jan; 52(1):474-491. PubMed ID: 38000387
[TBL] [Abstract][Full Text] [Related]
16. Ezh2-dCas9 and KRAB-dCas9 enable engineering of epigenetic memory in a context-dependent manner.
O'Geen H; Bates SL; Carter SS; Nisson KA; Halmai J; Fink KD; Rhie SK; Farnham PJ; Segal DJ
Epigenetics Chromatin; 2019 May; 12(1):26. PubMed ID: 31053162
[TBL] [Abstract][Full Text] [Related]
17. Antagonistic and synergistic epigenetic modulation using orthologous CRISPR/dCas9-based modular system.
Josipović G; Tadić V; Klasić M; Zanki V; Bečeheli I; Chung F; Ghantous A; Keser T; Madunić J; Bošković M; Lauc G; Herceg Z; Vojta A; Zoldoš V
Nucleic Acids Res; 2019 Oct; 47(18):9637-9657. PubMed ID: 31410472
[TBL] [Abstract][Full Text] [Related]
18. Determinants of heritable gene silencing for KRAB-dCas9 + DNMT3 and Ezh2-dCas9 + DNMT3 hit-and-run epigenome editing.
O'Geen H; Tomkova M; Combs JA; Tilley EK; Segal DJ
Nucleic Acids Res; 2022 Apr; 50(6):3239-3253. PubMed ID: 35234927
[TBL] [Abstract][Full Text] [Related]
19. Harnessing CRISPR-Cas9 for Epigenetic Engineering.
Guerra-Resendez RS; Hilton IB
Methods Mol Biol; 2022; 2518():237-251. PubMed ID: 35666449
[TBL] [Abstract][Full Text] [Related]
20. Targeted in vivo epigenome editing of H3K27me3.
Fukushima HS; Takeda H; Nakamura R
Epigenetics Chromatin; 2019 Mar; 12(1):17. PubMed ID: 30871638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
